Drug Development Portfolio and Spending Practices after Mergers and Acquisitions
- PDF / 9,929,144 Bytes
- 8 Pages / 612 x 792 pts (letter) Page_size
- 55 Downloads / 244 Views
Kmnnmtb A. Gmtx, MBA Senior Research Fellow, Tufts Center for the Study ofDrug Development (Tufts CSDD). Tufts University School ofMedicine, Boston, Massachusetts
Rotboml Zotkmnmm, BA Research Analyst. Tufts CSDD. Tufts University School ofMedicine. Boston, Massachusetts Jorepb A. DIMarl, PhD Director of Economic Analysis. Tufts CSDD. Tufts University School of Medicine. Boston. Massachusetts Kmnnmtb 1. Kritin, PbD Director, Professor of Medicine. Tufts CSDD. Tufts University School of Medicine. Boston. Massachusetts
Kmy Words Merger; Acquisition; M&A; Development pipeline forecasting Corrmspondm~tmAddrrrr Kenneth A. Getz. MBA. Senior Research Fellow, Tufts Centerfor the Study $Drug Development. 75 Kneeland St.. Suite 1100, Boston. MA 02111 (email: [email protected]). The Drug Information Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Drug Information Association designates this educational activity for a maximum of I AMA PRA Category 1 Physicians should only claim credit commensurate with the extent oftheirparticipotion in the activity. Ifyou would like to receive a stotcment ofcredit, you must review the article and complete the posttest and evaluation included on the DIA website. Participants must receive a passing score of 80% or better on the posttest in order to receive a statement olcredit. To access the posttest and evaluation. please visit the DIA website at www.diahome.org. select Educational Offerings. and then select Continuing Education from the dropdown menu, and the M y Transcript link. This will takeyou to the M y Transcript page whcreyou will be prompted lo sign in using your DIA username and password. Once signed in. you may select the article ‘Drug Development Portfolio and Spending Practices After Mergers and Acquisitions. “ You will be prompted to complete the posttest and evaluation. Upon successful completion o f t h e posttest. you will be able to downloadyour statement ofcredit. Ifyou are not a DIA customer. please contact the DIA office at mytranscript @diahome.org for a registration form. There is no/ee lo receive your statement ofcredit. Release Dale: /uly 1 , 2009 Expiration Date: July 31, 2010 Estimated time to complete the activity: I hour
493
Drug Development Portfolio and Spending Practices After Mergers and Acquisitions The recent vohune of merger and acquisition activity in the biopharmaceutical industry has been high and is expected to accdemte in 2009 and 2010duetoglobal economic conditions. In d e r to understand changes fdawing merger and acquisition @&A) in dinical meatrh investment and activi@ Tufts Center for the Study ofDevdopment analyzed ddopmentpipeheand spend~ngdatafor 24 of the largest independent M&As ocauring between 1998 and 2004 that each exceeded $1 billion in tmnsaction value. Organhations that had expenknced a merger or acquisition were evahurtedacmss three timeperiods and compand with industry benchmarks: 2 yems prior to an M&A announcement, an
Data Loading...
